Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma

Eirini Katodritou; Meletios A Dimopoulos; Konstantinos Zervas; Evangelos Terpos

doi:10.1016/j.ctrv.2009.08.002

Related publications

Article2012

The Use of Erythropoiesis-Stimulating Agents in the Intensive Care Unit

Michaël Piagnerelli, Jean Louis Vincent

Article2015

An update on the use of lenalidomide for the treatment of multiple myeloma

Flora Zagouri, Evangelos Terpos, Efstathios Kastritis, Meletios A Dimopoulos

Article2008

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin Kropff, Michel Delforge, Maria Teresa Petrucci, Victor Rossiev, Jian Hou, Tadeusz Robak, María‐Victoria Mateos, Kenneth C. Anderson, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel

Article2009

A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

PG Richardson, K Liu, William Deraedt, Helgi van de Velde, Rudolf Schlag, N Khuageva, Meletios A Dimopoulos, O Shpilberg, Martin Kropff, Michel Delforge, Maria Teresa Petrucci, Viktor Rossiev, Jie Hou, Tadeusz Robak, MV Mateos, KC Anderson, Andrew Cakana, Jesús F. San Miguel

Article2012

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment

Asher Chanan‐Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, Meletios A Dimopoulos